Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03512288 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
NCT03512288 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 460 participants.
The verdict
NCT03512288, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
Study Summary
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Interventions
- BIOLOGICAL 13vPnC
- BIOLOGICAL Multivalent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2020-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03512288
The ClinicalTrials.gov registry entry for NCT03512288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13vPnC is the first listed.
NCT03512288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03512288 about?
NCT03512288 is a clinical study titled "Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants". A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
What is the current status of trial NCT03512288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2018-04-16. Estimated completion is 2020-02-11.
What interventions are being tested in trial NCT03512288?
The interventions under investigation include: 13vPnC (BIOLOGICAL), Multivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT03512288?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.